Instem plc US Government Contract Win (8492Y)
February 28 2013 - 2:02AM
UK Regulatory
TIDMINS
RNS Number : 8492Y
Instem plc
28 February 2013
28 February 2013
Instem plc
("Instem", or, the "Company")
US Government Contract Win
Provantis Preclinical Software Chosen for National Toxicology
Program by National Institute of Environmental Health Sciences
Instem (AIM:INS), a leading provider of IT solutions to the
global early development healthcare market, announced today that
the National Institute of Environmental Health Sciences (NIEHS),
part of the National Institutes of Health (NIH), has purchased the
Provantis 9(R) preclinical software suite via SaaS
(Software-as-a-Service) to support National Toxicology Program
studies. These Reproductive, Immunotox, Neurobehavioural,
Sensitisation and Carcinogenicity studies are primarily carried out
at contractor laboratory sites throughout the United States.
The value of the award to Instem, funded completely by the US
government, is approximately $870,000 in the first year, with
potential to extend and expand the agreement up to a further 9
years, giving a possible total contract value for all 10 years of
between $6.2m-$7.6m. The contract also includes the ability to
expand to a larger number of additional sites on the same terms,
which could result in further material increase in revenue.
The National Toxicology Program (NTP) is an interagency program
established in 1978 to coordinate toxicology research and
development across the Department of Health and Human Services. The
program was also created to strengthen the science base in
toxicology, develop and validate improved testing methods and
provide information about potentially toxic chemicals to health
regulatory and research agencies, scientific and medical
communities, and the public.
Headquartered at NIEHS, the NTP is managed by the NIEHS and
supported by the United States Food and Drug Administration and the
Centers for Disease Control and Prevention.
Phil Reason, CEO of Instem plc, commented, "Such a significant
contract with the US government, won through a competitive
tendering process, is not only a fantastic endorsement of Instem's
innovative software but also of our strategy to support
collaborative working practices. Our SaaS delivery model enables
the sharing of the software between dispersed communities from
multiple organisations, The accessibility of Provantis data will
also enable the National Institute of Environmental Health Sciences
to meet a key goal of combining study information with a broader
set of biology information to improve scientific insights.
"This long term contract will also provide funding for the
development of the Provantis suite in areas specific to the
National Toxicology Program, adding further depth to our market
leading study management platform and positioning Instem well for
anticipated contract extensions and any similar future
projects."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT solutions to the early
development healthcare market. Instem's pre-clinical study
management solutions accelerate drug and chemical development by
increasing productivity, automating processes and enhancing
practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe,
Australia, China, India, Singapore and Japan, including 16 of the
top 20 pharmaceutical and biotech companies such as GlaxoSmithKline
and AstraZeneca. The Group employs over 110 people in seven offices
in the US, UK, China and India; and has a full service distributor
in Japan. It is estimated that approximately half of the world's
pre-clinical drug safety data has been collected over the last 20
years via Instem software, making Instem an ideal partner to help
unlock the scientific/commercial value from these legacy
repositories.
To learn more about Instem please visit the Company's website,
www.instem.com, or its investor centre
http://investors.instem.com/
About NIEHS
The NIEHS supports research to understand the effects of the
environment on human health and is part of the National Institutes
of Health (NIH). Its mission is to reduce the burden of human
illness and disability by understanding how the environment
influences the development and progression of human disease.
For more information on environmental health topics, visit
www.niehs.nih.gov.
The NIH - The Nation's Medical Research Agency - includes 27
Institutes and Centers and is a component of the U.S. Department of
Health and Human Services. It is the primary federal agency for
conducting and supporting basic, clinical and translational medical
research, and it investigates the causes, treatments, and cures for
both common and rare diseases. For more information about NIH and
its programs, visit www.nih.gov.
This project has been funded in whole or in part with Federal
funds from the National Institute of Environmental Health Sciences,
National Institutes of Health, Department of Health and Human
Services, under Contract No. HHSN27320130004C.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTDXGDDSBDBGXR
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024